Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

Study:

Phase II Study of BAY 56-3722 in Patients With Recurrent, Unresectable, or Metastatic Renal Cell Carcinoma

Rationale:

BAY 56-3722 may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth.

Purpose:

Phase II trial to study the effectiveness of BAY 56-3722 in treating patients who have recurrent, unresectable, or metastatic kidney cancer.

Study Status: Withdrawn

Recruiting:
n/a

Condition Intervention Phase
Stage IV Renal Cell Cancer
Recurrent Renal Cell Cancer
Drug: BAY 56-3722
Procedure: enzyme inhibitor therapy
Phase 2

Verified by Jonsson Comprehensive Cancer Center December, 2006

Sponsored by: Jonsson Comprehensive Cancer Center
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00040989

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Barbara J. Gitlitz, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site